Source:http://linkedlifedata.com/resource/pubmed/id/17458173
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-4-26
|
| pubmed:abstractText |
Therion Biologics Corp is developing PROSTVAC-VF-TRICOM, a prime-boost vaccine regimen that consists of a priming injection with a recombinant attenuated vaccinia virus expressing PSA and TRICOM (the company's proprietary triad of costimulatory molecules: ICAM-1, B7.1 and lymphocyte function-associated antigen-3), and a booster injection with a fowlpox virus expressing the same combination, for the potential treatment of prostate cancer. Phase II clinical trials are underway.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1464-8431
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
183-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:17458173-Cancer Vaccines,
pubmed-meshheading:17458173-Clinical Trials, Phase I as Topic,
pubmed-meshheading:17458173-Clinical Trials, Phase II as Topic,
pubmed-meshheading:17458173-Clinical Trials, Phase III as Topic,
pubmed-meshheading:17458173-Drug Evaluation, Preclinical,
pubmed-meshheading:17458173-Humans,
pubmed-meshheading:17458173-Male,
pubmed-meshheading:17458173-Patents as Topic,
pubmed-meshheading:17458173-Prostatic Neoplasms,
pubmed-meshheading:17458173-Structure-Activity Relationship
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
|
| pubmed:affiliation |
University of Lübeck Medical School, Department of Urology, Ratzeburger Allee 160, 23538 Lübeck, Germany. doehn@medinf.mu-luebeck.de
|
| pubmed:publicationType |
Journal Article
|